Open-label, Non-randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety and Tolerability of a Single Dose of CHF 5993 pMDI in Subjects With Mild, Moderate and Severe Renal Impairment in Comparison With Matched Healthy Control Subjects.

Trial Profile

Open-label, Non-randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety and Tolerability of a Single Dose of CHF 5993 pMDI in Subjects With Mild, Moderate and Severe Renal Impairment in Comparison With Matched Healthy Control Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Beclometasone/formoterol/glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Acronyms TRIPLE10
  • Sponsors Chiesi Farmaceutici SpA
  • Most Recent Events

    • 30 Jul 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 03 Feb 2015 Planned End Date changed from 1 Feb 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 03 Feb 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top